Over the last six months, we’ve seen the global community lose up to $8 trillion of value, only to recover shortly after. In fact, since February 2016, the Dow has rallied 17% from a low of 15,503. The NASDAQ ran 13% from a low of 4,376. The S&P 500 rocketed 17% from a low of…
DetailsYesterday we looked at how “Gold Banking” is delivering massive returns for gold investors. Gold Banking is a simple premise that excels in a bull market. Step 1: Accumulate gold reserves and resources which are uneconomical to mine at current gold prices for pennies on the eventual dollar. Step 2: Watch the value of them…
DetailsIt may not be one of the most exciting stocks. But it’s making a great deal of money for smart investors. The company – Planet Payment (PLPM) isn’t really anything exciting at all. It simply provides international payment and transaction processing services in 21 countries and territories across the Asia-Pacific, the Americas, the Middle East,…
DetailsThis is the hottest trend in gold stocks right now. It’s a simple idea. It’s historically proven. And the small group of companies using this strategy are trouncing the rest of the gold market by three or four times over.
DetailsDon’t buy all the Fed-fueled hype. The next Federal Reserve meeting is next week. It should be a complete non-event. Based on interest rate futures pricing, there is a 1-in-25 chance the Fed will raise short-term interest rates. With odds like that, any other move would spook the markets and stocks, bonds, and gold would…
DetailsThe buyout rumors are heating up. After the FDA granted approval for ACAD’s Parkinson’s disease Psychosis (PDP) treatment, the list of potential acquirers is getting longer. Not only is Pfizer, Biotgen, and Teva reportedly interested in the company, but now reports are surfacing that AstraZeneca may be a potential bidder, too. Sources say ACADIA may…
DetailsAs the U.S. economy slows, we would expect to see evidence of this in unemployment numbers, which is exactly what we’re seeing. In fact, new evidence proves the economy is not on the mend, as hoped. In May, the economy added just 38,000 jobs – the weakest showing in six years and far short of…
DetailsYesterday’s employment report was awful. The Bureau of Labor Statistics said 38,000 jobs were added in May. Wall Street was expecting 168,000. A miss by any measure. There was some good news though. The “official” unemployment rate dropped 0.3% to 4.7% and should finally have lost all remaining credibility. Normally, we’d say this is just…
DetailsDo you own any gold stocks? Are you considering taking the recent correction as a chance to take some profits? Or as a second chance to jump on? Either way, you’ve got to see this chart to understand the position gold stocks are in right now and whether they’re for you at all.
DetailsOver the last year, The Cheap Investor made a recommendation to buy Galena Biopharma (GALE) at just $1.33 in June 2015, and again at $1.67 in August 2015. As of today, the stock last traded at $2.29 for potential gains of 37% and 80%. The stock is tracking even higher after the FDA designated its…
DetailsIt’s become one of the best stocks to own over the last seven months. At just $1.75 a share, Celator Pharmaceuticals (CPXX) wasn’t considered anything special. Except for the fact it truly was…and is… Largely ignored by analysts and investors for years, we found value, recommending it in the November 2015 issue of The Cheap…
DetailsIn the November 2015 issue of The Cheap Investor, we made a recommendation to pick up shares of CPXX at just $1.75 a share. Just months later, the stock skyrocketed to a high of $17.69 for potential gains of 911% on news of successful Phase III clinical results for VYXEOS for patients with high risk…
Details